Vanda settles its squabble with Novartis and pockets $25M for its trouble

Vanda Pharmaceuticals ($VNDA) has come out at the other end of its dispute with former partner Novartis ($NVS), getting back the rights to its schizophrenia drug and banking an equity investment from the Swiss drugmaker.

In 2009, Novartis bought the U.S. and Canadian rights to Vanda's Fanapt in a deal worth up to $465 million, working to crack the market with what many perceived as a me-too drug. Fanapt never lived up to the partners' hopes, however, and the deal bubbled over into a dispute this May, with Vanda demanding $539 million and Novartis responding with a counter claim.

Now, under the pair's final agreement, Vanda regains the full rights to Fanapt, and Novartis has agreed to make a $25 million investment in the company. Vanda also gets a worldwide exclusive license to Novartis' AQW051, a Phase II treatment for schizophrenia.

The deal "has the potential to be transformational for our company," CEO Mihael Polymeropoulos said in a statement, and the news sent Vanda's shares soaring more than 20% on Tuesday morning.

Beyond Fanapt, Vanda's portfolio includes Hetlioz, approved early this year to treat a sleep disorder called non-24, and VLY-686, an anti-itching drug.

- read the statement

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.